Loading news...
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investo.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia.
WALTHAM, Mass.--(BUSINESS WIRE)--Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 3:00 pm ET. A live webcast of the company presentation will be available on the Company's website at www.korsana.com. A replay.
MIAMI & SEOUL, South Korea--(BUSINESS WIRE)--LG CNS Co., Ltd. and Palantir Technologies Inc. (NASDAQ: PLTR), a leading provider of AI operating systems, today announced a deepened strategic partnership aimed at accelerating AI Transformation (AX) initiatives across LG Group. The announcement was made ahead of Palantir's AIPCon, where the two companies formalized their joint ambition to bring transformational business impact to the diverse portfolio of companies within one of the world's largest.
Investors with an interest in Financial - Investment Management stocks have likely encountered both Janus Henderson Group plc (JHG) and Cohen & Steers Inc (CNS). But which of these two stocks offers value investors a better bang for their buck right now?
NEW YORK, March 11, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced plans to convert the Cohen & Steers Future of Energy Fund, a U.S. mutual fund designed to capitalize on opportunities across traditional and alternative energy, into an actively managed exchange-traded fund ("ETF"). The ETF will be managed by the same portfolio management team and pursue the same investment objectives as the current mutual fund.
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areas Company pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287 HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development.
SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform.
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.
NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET.
NEW YORK, March 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $98.4 billion as of February 28, 2026, an increase of $5.4 billion from assets under management of $93.1 billion at January 31, 2026. The increase was due to market appreciation of $5.5 billion and net inflows of $7 million, partially offset by distributions of $151 million.
Stock News Oil tops $100 as supply risks mount: Brent surged intraday to $119 and WTI neared $119 amid a near-halt through the Strait of Hormuz and strikes on e
Citigroup Inc. cut its stake in shares of Cohen and Steers Inc (NYSE: CNS) by 21.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,773 shares of the asset manager's stock after selling 8,948 shares during the quarter. Citigroup
Fisher Asset Management LLC raised its holdings in shares of Cohen and Steers Inc (NYSE: CNS) by 12.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 111,334 shares of the asset manager's stock after purchasing an additional
Recognition highlights global scale, performance leadership, and service availability expertise LONDON, March 5, 2026 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a leader in real-time DDoS protection and service availability, today announced it has been named a "Star" in the MarketsandMarkets DDoS Protection & Mitigation Security Market report. Positioned in the "Stars" quadrant, Corero earned "Excellent" ratings across all major footprint categories: regional presence, offering breadth, vertical focus, and overall execution.
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder value HOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than two decades of global leadership experience across clinical development, translational medicine and regulatory strategy in oncology, rare diseases, CNS and medical devices.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on February 27, 2026 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, Feb. 26, 2026 /PRNewswire/ --This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on February 27, 2026 and cumulative distributions paid fiscal year-to-date. In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on February 27, 2026 and cumulative distributions paid fiscal year-to-date. In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.